Guarionex Joel DeCastro
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Year:
2026
Year:
2026
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2025
Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50
Year:
2025
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2025
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2024
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2024
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2024
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2024
Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50
Year:
2024
Year:
2024
Year:
2024
Collaborators (25)
Joseph G. Jurcic
Columbia University Irving Medical Center
Prabhjot Mundi
Assistant Professor
Columbia University Irving Medical Center
Peter Sims
Assistant Professor
Columbia University Irving Medical Center
Hanina Hibshoosh
Professor of pathology at CUIMC
Columbia University
Guy M. McKhann
Florence Irving Associate Professor of Neurological Surgery
Columbia University Irving Medical Center
Ana Tergas
Rutgers, The State Univ. of NJ
Kenneth Olive
Assistant Dean of Graduate Curricula and Associate Professor of Medicine
Columbia University Irving Medical Center
Casey Ager
Assistant Professor
Mayo Clinic Arizona
Jason D. Wright
-
Andrew Kung
Chair
Memorial Sloan Kettering Cancer Center
Mariano Alvarez
Chief Scientific Officer
KweHealth, LLC
Gary K. Schwartz
Case Western Reserve University
Andrew Lassman
Chief, Neuro-Oncology Division
Columbia University Irving Medical Center
Dawn L. Hershman
Columbia University Irving Medical Center
Mark Stein
Associate Professor
Columbia University Irving Medical Center
Kevin Kalinsky
Emory University
Katherine Crew
Professor
Columbia University Irving Medical Center
Alfred I. Neugut
-
Daniel Diolaiti
Fred Hutchinson Cancer Research Center
Michael Kluger
Professor of Surgery
NYU Langone Health
Andrea Califano
Columbia University Irving Medical Center
Eugene Douglass
Assistant Professor
University of Georgia
Catherine Shu
Columbia University Irving Medical Center
Melissa K. Accordino
Columbia University
Jeffrey Bruce
NewYork-Presbyterian Hospital/Columbia University Irving Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.